Risks and Lack of Evidence for Unvalidated Multi‑Cancer Blood Tests

Potential Harm from Inaccurate Results

• False‑negative results from unvalidated multi‑cancer blood tests can give patients false reassurance, delay diagnosis of symptomatic cancers, and lead to later‑stage disease and increased mortality (expert opinion) 3
• False‑positive results may trigger unnecessary invasive diagnostic procedures and cause significant patient anxiety (expert opinion) 4

Misleading Marketing and Regulatory Misconceptions

• Promotion of multi‑cancer blood tests without peer‑reviewed evidence misleads clinicians and patients and creates clear potential for harm (expert opinion) 3
• FDA clearance of a test does not equate to evidence‑based effectiveness for cancer screening (expert opinion) 4

Clinical Practice Recommendations

• Experts advise against prescribing or recommending multi‑cancer blood tests that lack peer‑reviewed validation in average‑risk populations, due to insufficient evidence of benefit and safety (expert opinion) 3
• Clinicians should not replace guideline‑endorsed, evidence‑based cancer screening modalities with unvalidated blood‑based tests (expert opinion) 4